Tags

Type your tag names separated by a space and hit enter

[Pharmacotherapy of obesity].
Internist (Berl). 2008 Jan; 49(1):106-13.I

Abstract

Diet, exercise and behavioral therapy are the basics for every treatment of obesity. If lifestyle intervention does not result in a weight loss of 5% within 3 to 6 months, an additional pharmacotherapy can be considered. Treated patients should have a BMI >/=30 kg/m(2) or at least a BMI >/=27 kg/m(2) plus accompanying comorbidities, such as type 2 diabetes, dyslipidemia or hypertension. Current guidelines list orlistat, sibutramine and rimonabant as possible options for the pharmacotherapy of obesity. These compounds result in moderate weight reduction and improvement of cardiovascular risk profile. Especially the improvement of glucose metabolism can be considered as clinically relevant. Different side effects of the various compounds need to be considered before their use. Additional options for the pharmacotherapy of obesity are currently developed, their approval, however, is unlikely to happen within the next couple of years.

Authors+Show Affiliations

Diabetes-Klinik Bad Nauheim GmbH, Campus für Herz- und Gefässmedizin, Ludwigstrasse 37-39, 61231, Bad Nauheim, Deutschland. a.hamann.diabetes@pitzer-kliniken.de

Pub Type(s)

Journal Article
Review

Language

ger

PubMed ID

18060334

Citation

Hamann, A. "[Pharmacotherapy of Obesity]." Der Internist, vol. 49, no. 1, 2008, pp. 106-13.
Hamann A. [Pharmacotherapy of obesity]. Internist (Berl). 2008;49(1):106-13.
Hamann, A. (2008). [Pharmacotherapy of obesity]. Der Internist, 49(1), 106-13.
Hamann A. [Pharmacotherapy of Obesity]. Internist (Berl). 2008;49(1):106-13. PubMed PMID: 18060334.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Pharmacotherapy of obesity]. A1 - Hamann,A, PY - 2007/12/7/pubmed PY - 2009/4/2/medline PY - 2007/12/7/entrez SP - 106 EP - 13 JF - Der Internist JO - Internist (Berl) VL - 49 IS - 1 N2 - Diet, exercise and behavioral therapy are the basics for every treatment of obesity. If lifestyle intervention does not result in a weight loss of 5% within 3 to 6 months, an additional pharmacotherapy can be considered. Treated patients should have a BMI >/=30 kg/m(2) or at least a BMI >/=27 kg/m(2) plus accompanying comorbidities, such as type 2 diabetes, dyslipidemia or hypertension. Current guidelines list orlistat, sibutramine and rimonabant as possible options for the pharmacotherapy of obesity. These compounds result in moderate weight reduction and improvement of cardiovascular risk profile. Especially the improvement of glucose metabolism can be considered as clinically relevant. Different side effects of the various compounds need to be considered before their use. Additional options for the pharmacotherapy of obesity are currently developed, their approval, however, is unlikely to happen within the next couple of years. SN - 1432-1289 UR - https://www.unboundmedicine.com/medline/citation/18060334/[Pharmacotherapy_of_obesity]_ L2 - https://dx.doi.org/10.1007/s00108-007-1981-z DB - PRIME DP - Unbound Medicine ER -